Skip to main content
. 2017 Sep;9(9):3123–3131. doi: 10.21037/jtd.2017.08.68

Figure 3.

Figure 3

Kaplan-Meier survival curves for patients with lower (L) or higher (H) baseline levels in neutrophil-to-lymphocyte ratio (NLR) (A) and patients with L or H baseline levels of IL-17 (B). Our analysis showed that the patients with L baseline levels in NLR have a longer survival than patients with high baseline levels of NLR [mean OS L vs. H: 24.95 months (95% CI: 7.80–42.04) vs. 9.88 months (95% CI: 2.49–17.27), P=0.05]. Moreover, patients with L baseline levels of IL-17 have a longer survival than patients with H baseline levels of IL-17 [mean OS L vs. H: 34.63 months (95% CI: 7.84–61.44) vs. 11 (95% CI: 5.14–16.85), P=0.036]. OS, overall survival.